VIR Q2 2023 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+109.3% YoY

Gross Profit

-$164M-4327.3% margin

Operating Income

-$215M-5667.3% margin

Net Income

-$195M-5129.7% margin

EPS (Diluted)

$-1.45

QoQ Revenue Growth

-94.0%

Cash Flow

Operating Cash Flow

-$389M

Free Cash Flow

-$399M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$434M

Stockholders' Equity

$1.8B

Cash & Equivalents

$667M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	-$41M	+109.3%
Gross Profit	-$164M	-$184M	+10.5%
Operating Income	-$215M	-$225M	+4.5%
Net Income	-$195M	-$76M	-154.6%

Revenue Segments

Grant

$17M94%

Contract Revenue

$1M6%